Breast and ovarian cancer risk evaluation in families with a disease-causing mutation in BRCA1/2

被引：3

作者：

Beristain E. ^{[1
]}

Ibáñez B. ^{[2
]}

Vergara I. ^{[2
]}

Martínez-Bouzas C. ^{[1
]}

Guerra I. ^{[3
]}

Tejada M.I. ^{[1
]}

机构：

[1] Molecular Genetics Laboratory, Biochemistry Department, Hospital de Cruces, 48903 Barakaldo, Bizkaia, Plaza de Cruces s/n

[2] Basque Foundation for Health Innovation and Research (BIOEF), 48150 Sondika, Plaza de Asua s/n

[3] Anatomy and Pathology Department, Hospital de Txagorritxu, 01006 Vitoria-Gasteiz, Jose Atxotegi s/n

来源：

Journal of Community Genetics | 2010年 / 1卷 / 2期

关键词：

Breast cancer; Cumulative risk; Ovarian cancer; Penetrance;

D O I：

10.1007/s12687-010-0014-0

中图分类号：

学科分类号：

摘要：

Germline mutations in BRCA1 and BRCA2 confer high risks of breast and ovarian cancer, and their identification allows genetic testing of at-risk relatives. However, estimates of these risks illustrate controversies, depending on the published series. The penetrance, the earlier onset of the disease and the effect of mutations on the risk of developing breast and ovarian cancer were evaluated in 344 females belonging to 34 families from the Basque Country in Spain, in which BRCA1 or BRCA2 mutations were transmitted. Kaplan-Meier survival curves were used to derive cumulative probability curves for breast and ovarian cancer by mutation status, birth cohort and mutation position, and significance of the differences was assessed using the logrank test. The estimated probability for breast cancer by age 70 is about 64% in BRCA1 and 69% in BRCA2, whereas the probability of developing ovarian cancer is about 37% and 25% for BRCA1 and BRCA2, respectively. There is a marginally significant higher risk of developing ovarian cancer in BRCA1 families than in BRCA2 families. The effect of birth cohort on breast cancer cumulative incidence presents an increased risk for females born after 1966 and a decreased risk for those born before 1940. There is no association between mutation position and breast cancer; however, ovarian cancer is associated to BRCA1, presenting exon 11 as an ovarian cluster. These results are important for the breast and ovarian cancer diagnosis and prevention in atrisk families. © Springer-Verlag 2010.

引用

页码：91 / 99

页数：8

共 25 条

[1]

Al-Mulla F., Bland J.M., Serratt D., Et al., Age-dependent penetrance of different germline mutations in the BRCA1 gene, J Clin Pathol, 62, pp. 350-356, (2009)

[2]

Al-Saffar M., Foulkes W.D., Hereditary ovarian cancer resulting from a non-ovarian cancer cluster region (OCCR) BRCA2 mutation: Is the OCCR useful clinically?, J Med Genet, 39, (2002)

[3]

Antoniou A., Pharoah P.D.P., Narod S., Risch H.A., Eyfjord J.E., Hopper J.L., Loman N., Olsson H., Johannsson O., Borg A., Pasini B., Radice P., Manoukian S., Eccles D.M., Tang N., Olah E., Anton-Culver H., Warner E., Lubinski J., Gronwald J., Gorski B., Tulinius H., Thorlacius S., Eerola H., Nevanlinna H., Syrjakoski K., Kallioniemi O.-P., Thompson D., Evans C., Peto J., Lalloo F., Evans D.G., Easton D.F., Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations dete

[4]

Antoniou A., Durocher F., Smith P., Et al., INHERIT BRCAs program members, Easton DF: BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families, Breast Cancer Res, 8, (2006)

[5]

Asua J., Rico R., Gutierrez M.A., Aranaez R., Detección Precoz Del Cáncer de Mama en la CAPV, (1994)

[6]

Begg C.B., On the use of familial aggregation in population-based case probands for calculating penetrance, Journal of the National Cancer Institute, 94, 16, pp. 1221-1226, (2002)

[7]

Beristain E., Martinez-Bouzas C., Guerra I., Viguera N., Moreno J., Ibanez E., Diez J., Rodriguez F., Mallabiabarrena G., Lujan S., Gorostiaga J., De Pablo J.L., Mendizabal J.L., Tejada M.I., Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: Implications for genetic counselling, Breast Cancer Research and Treatment, 106, 2, pp. 255-262, (2007)

[8]

Beristain E., Martinez-Bouzas C., Mallabiabarrena G., Et al., Is early onset breast cancer with no family history a good criterion for testing BRCA1 and BRCA2 genes?: A small population-based study, Clin Genet, 75, 6, pp. 576-578, (2009)

[9]

Couch F.J., DeShano M.L., Blackwood M.A., Calzone K., Stopfer J., Campeau L., Ganguly A., Rebbeck T., Weber B.L., Jablon L., Cobleigh M.A., Hoskins K., Garber J.E., BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer, New England Journal of Medicine, 336, 20, pp. 1409-1415, (1997)

[10]

Coyle Y.M., Lifestyle, Genes and Cancer. Methods of Molecular Biology, Cancer Epidemiology, 472, (2009)

← 1 2 3 →